Last reviewed · How we verify
recombinant human interleukin-21
At a glance
| Generic name | recombinant human interleukin-21 |
|---|---|
| Sponsor | NCIC Clinical Trials Group |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1 First-in-human Study of JS014 (PHASE1)
- Efficacy Study of IL-21 to Treat Metastatic Melanoma (PHASE2)
- Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma (PHASE2)
- Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients (PHASE2)
- Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors (PHASE1)
- Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer (PHASE1)
- Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant human interleukin-21 CI brief — competitive landscape report
- recombinant human interleukin-21 updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI